Skip to main content
SpringerLink
Log in
Book cover

Thyroid Cancer pp 103–113Cite as

Recombinant Human Thyrotropin

  • Chapter

Abstract

Initial management of patients with thyroid cancer generally includes surgical thyroidectomy, eradication of iodineavid tissue (benign or malignant) with radioactive iodine, and long-term treatment with L-thyroxine at doses sufficient for suppression of pituitary production of thyrotropin (TSH; 1,2). Thyroid cancer recurs in 20–40% of patients, requiring long-term monitoring for tumor recurrence or progression (3). Similar to most other malignancies, monitoring is done by physical examination, measurement of tissue or tumor-specific serum markers, and radiographic and sonographic imaging. Measurements of serum thyroglobulin concentrations and radioiodine whole-body imaging are used most frequently to monitor thyroid cancer patients (1,4). Both of these modalities measure relatively thyroid-specific functions. However, the sensitivities of iodine scanning and thyroglobulin measurement are limited by the small, relative amount of thyroid tissue present in patients treated by thyroidectomy and dedifferentiation of tumor cells compared to normal thyrocytes. Therefore, for optimal sensitivity, both radioiodine imaging and serum thyroglobulin measurement require stimulation of thyroid tissue by elevated TSH levels. Moreover, elevated serum concentrations of TSH are also required for radioiodine therapy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   269.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   339.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996; 156:2165–2172.

    Article  PubMed  CAS  Google Scholar 

  2. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81:333–339.

    Article  PubMed  CAS  Google Scholar 

  3. Mazzaferri EL, Jiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular cancer. Am J Med 1994; 89:418–428.

    Article  Google Scholar 

  4. Ozata M, Suzuki S, Miyamoto T, et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 778:188–196.

    Google Scholar 

  5. Dow KH, Ferrell BR, Annelo C. Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997; 7:613–619.

    PubMed  CAS  Google Scholar 

  6. Billewicz WZ, Chapman RS, Crooks J, et al. Statistical methods applied to the diagnosis of hypothyroidism. Q J Med 1969; 38:255–266.

    PubMed  CAS  Google Scholar 

  7. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337:888–896.

    Article  PubMed  CAS  Google Scholar 

  8. Stakianakis GN, Stillman TG, George JM. Thyroxine withdrawal in thyroid cancer. Ohio State Med J 1975; 71:79–82.

    Google Scholar 

  9. Goldberg LD, Ditchek NT. Thyroid carcinoma with spinal cord compression. JAMA 1981; 245:953–954.

    Article  PubMed  CAS  Google Scholar 

  10. Guimaraes V, Degroot LJ. Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing. Thyroid 1996; 6:69–73.

    PubMed  CAS  Google Scholar 

  11. Maxon HR. Recombinant human thyrotropin symposium: Detection of residual and recurrent thyroid cancer by radionuclide imaging. Thyroid 1999; 9:443–446.

    PubMed  CAS  Google Scholar 

  12. Robbins J. Recombinant human thyrotropin seminar: Pharmacology of bovine and human thyrotropin: an historical perspective. Thyroid 1999; 9:451–453.

    PubMed  CAS  Google Scholar 

  13. Wide L, Dahlberg PA. Quality requirements of basal S-TSH assays in predicting an S-TSH response to TRH. Scand J Clin Lab Invest 1981; 40:101.

    Google Scholar 

  14. Sawin CT, Hershman JM. The TSH response to thyrotropin-releasing hormone (TRH) in young adult men: intra-individual variation and relation to basal serum TSH and thyroid hormones. J Clin Endocrinol Metab 1976; 42:809–816.

    PubMed  CAS  Google Scholar 

  15. Spencer CA, Schwarzbein D, Guttler RB, et al. Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assays. J Clin Endocrinol Metab 1993; 76:494–498.

    Article  PubMed  CAS  Google Scholar 

  16. Fairclough PD, Cryer RJ, McAllister J, et al. Serum TSH responses to intravenously and orally administered TRH in man after thyroidectomy for carcinoma of the thyroid. Clin Endocrinol 1973; 2:351–359.

    CAS  Google Scholar 

  17. Wenzel KW, Meinhold H, Bogner U, et al. Serum TSH levels in thyroidectomized patients after withdrawal of thyroid hormone therapy or oral administration of TRH. Acta Endocrinol 1973; 173 (Suppl):15.

    CAS  Google Scholar 

  18. Eissner D, Hahn K, Grimm W. Oral TRH stimulation in patients with thyroid carcinoma. ROFO 1983; 138:95–100.

    PubMed  CAS  Google Scholar 

  19. Ang ES, Teh HS, Sundram FX, Lee KO. Effect of lithium and oral thyrotrophin-releasing hormone (TRH) on serum thyrotrophin (TSH) and radioiodine uptake in patients with well differentiated thyroid carcinoma. Singapore Med J 1995; 36:606–608.

    PubMed  CAS  Google Scholar 

  20. Magner JA, Kane J, Chou ET. Intravenous thyrotropin (TSH)-releasing hormone releases human TSH that is structurally different from basal TSH. J Clin Endocrinol Metab 1992; 74:1306–1311.

    Article  PubMed  CAS  Google Scholar 

  21. Schaaf L, Leiprecht A, Saji M, et al. Glycosylation variants of human TSH selectively activate signal transduction pathways. Mol Cell Endocrinol 1997; 132:185–194.

    Article  PubMed  CAS  Google Scholar 

  22. Szkudinski MW, Thokatura NR, Weintraub BD. Subunit-specific functions of N-linked oligosaccharides in human thyrotropin: role of terminal residues of alpha and beta subunit oligosaccharides in clearance and bioactivity. Proc Natl Acad Sci USA 1995; 92:9062–9066.

    Article  Google Scholar 

  23. Cannone C, Papandreou MJ, Medri G, et al. Biological and immunochemical characterization of recombinant human thyrotrophin. Glycobiology 1995; 5:473–481.

    Article  Google Scholar 

  24. Szkudlinski MW, Thokatura NR, Bucci I, et al. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology 1993; 133:1490–1503.

    Article  PubMed  CAS  Google Scholar 

  25. Thokatura NR, Desai RK, Bates LG, et al. Biological activity and metabolic clearance of a recombinant human thyrotropin produces in Chinese hamster ovary cells. Endocrinology 1991; 128:341–348.

    Google Scholar 

  26. Thokatura NR, Szkudlinski MW, Weintraub BD. Structure-function studies of oligosaccharides of recombinant human thyrotropin by sequential deglycosylation and resialylation. Glycobiology 1994; 4:525–533.

    Article  Google Scholar 

  27. Matzuk MM, Kornmeier CM, Whitfield GK, et al. The glycoprotein-subunit is critical for secretion and stability of the human thyrotropin β-subunit. Mol Endocrinol 1 1988; 2:95–100.

    CAS  Google Scholar 

  28. Seidlin SM, Oshry E, Yalow AA. Spontaneous and experimentally induced uptake of radioactive iodine in metastases from thyroid carcinoma: a preliminary report. J Clin Endocrinol 1948; 8:423–432.

    CAS  Google Scholar 

  29. Stanley MM, Astwood EB. The response of the thyroid gland in normal human subjects to the administration of thyrotropin, as shown by studies with I-131. Endocrinology 1949; 44:49–60.

    CAS  PubMed  Google Scholar 

  30. Benua RS, Sonenberg M, Leeper RD, Rawson RW. An 18 year study of the use of beef thyrotropin to increase I-131 uptake in metastatic thyroid cancer. J Nucl Med 1964; 5:796–801.

    Google Scholar 

  31. Sturgeon CT, Davis FE, Catz B, et al. Treatment of thyroid cancer metastases with TSH and I-131 during thyroid hormone medication. J Clin Endocrinol Metab 1953; 13:1391–1407.

    PubMed  CAS  Google Scholar 

  32. Catz B, Petit D, Starr P. The diagnostic and therapeutic value of thyrotropic hormone and heavy dosage scintigrams for the demonstration of thyroid cancer metastases. Am J Med Sci 1959; 237:158–164.

    PubMed  CAS  Google Scholar 

  33. Catz B, Petit DW, Schwartz M, et al. Treatment of cancer of the thyroid postoperatively with suppressive thyroid medication, radioiodine, and thyroid-stimulating hormone. Cancer 1959; 12:371–383.

    Article  PubMed  CAS  Google Scholar 

  34. Reichert LE Jr. On the relationship between human thyrotrophin research standard A, the United States Pharmacopeia thyrotrophin standard (bovine) and the International Standard for thyrotrophin (bovine). J Clin Endocrinol 1970; 31:331–333.

    CAS  Google Scholar 

  35. Schneider PB, Robbins J, Condliffe PG. Thyroid response to human thyrotropin in man. J Clin Endocrinol Metab 1965; 25:514–517.

    PubMed  CAS  Google Scholar 

  36. Hershman JM, Edwards CL. Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: implications for 131I treatment of thyroid carcinoma. J Clin Endocrinol 1972; 34:814–818.

    CAS  Google Scholar 

  37. Hays MT, Solomon DH, Werner SC. The effect of purified bovine thyroid-stimulating hormone in man. II. Loss of effectiveness with prolonged administration. J Clin Endocrinol Metab 1961; 21:1475–1482.

    PubMed  CAS  Google Scholar 

  38. Krishnamurthy GT. Human reactive to bovine TSH: concise communication. J Nucl Med 1978; 19:284–286.

    PubMed  CAS  Google Scholar 

  39. Sherman WB, Werner SC. Generalized allergic reaction to bovine thyrotropin. JAMA 1964; 190:244–245.

    PubMed  CAS  Google Scholar 

  40. Hays MT, Solomon DH, Pierce JG, Carsten ME. The effect of purified bovine thyroid-stimulating hormone in man. I. Dose-response characteristics studies with I132. J Clin Endocrinol Metab 1961; 21:1469–1474.

    PubMed  CAS  Google Scholar 

  41. Melmed S, Harada A, Hershman JM, Krishnamurthy GT, Bland WH. Neutralizing antibodies to bovine thyrotropin in immunized patients with thyroid cancer. J Clin Endocrinol Metab 1980; 51:358–363.

    PubMed  CAS  Google Scholar 

  42. Hays MT, Solomon DH, Beall GN. Suppression of human thyroid function by antibodies to bovine thyrotropin. J Clin Endocrinol Metab 1967; 27:1540–1549.

    PubMed  CAS  Google Scholar 

  43. Greenspan FS, Lowenstein JM, West MN, Okerlund MD. Immunoreactive material to bovine TSH in plasma from patients with thyroid cancer. J Clin Endocrinol Metab 1972; 35:795–798.

    Article  PubMed  CAS  Google Scholar 

  44. Frohman LA, Baron MA, Schneider AB. Plasma immunoreactive TSH: spurious elevation due to antibodies to bovine TSH which crossreact with human TSH. Metabolism 1982; 31:834–840.

    Article  PubMed  CAS  Google Scholar 

  45. Greenspan FS, Lew W, Okerlund MD, et al. Falsely positive bovine TSH radioimmunoassay responses in sera from patients with thyroid cancer. J Clin Endocrinol Metab 1974; 38:1121–1122.

    PubMed  CAS  Google Scholar 

  46. Sain A, Sham R, Singh A, et al. Erroneous thyroid-stimulating hormone radioimmunoassay results due to interfering anti-bovine thyroidstimulating hormone antibodies. Am J Clin Pathol 1979; 71:540–542.

    PubMed  CAS  Google Scholar 

  47. Chaussain JL, Binet E, Job JC. Antibodies to human thyrotropin in the serum of certain hypopituitary dwarfs. Rev Eur Etudes Clin Biol 1972; 17:95–99.

    CAS  Google Scholar 

  48. Uller RP, van Herle AJ, Chopra IJ. Comparison of alterations in circulating thyroglobulin, triiodothyronine and thyroxine in response to exogenous (bovine) and endogenous (human) thyrotropin. J Clin Endocrinol Metab 1973; 37:741–745.

    PubMed  CAS  Google Scholar 

  49. Kuku SF, Harsoulle P, Kjed M, Fraser TR. Human thyrotrophic hormone kinetics and effects in euthyroid males. Horm Metab Res 1975; 7:54–59.

    CAS  Google Scholar 

  50. Law A, Jack GW, Tellez M, Edmonds CJ. In vivo studies of a human thyrotrophin preparation. J Clin Endocrinol 1986; 110:375–378.

    CAS  Google Scholar 

  51. Ridgway EC, Weintraub BD, Maloof F. Metabolic clearance and production rates of human thyrotropin. J Clin Invest 1974; 53:8895–8903.

    Article  Google Scholar 

  52. Brown P, Gadjusek DC, Gibbs Jr CJ, Asher DM. Potential epidemic of Creutzfeld-Jakob disease from human growth hormone therapy. N Engl J Med 1985; 110:375–378.

    Google Scholar 

  53. Hayashizaki Y, Miyai K, Kato K, Matsubara K. Molecular cloning of the human thyrotropin beta-subunit gene. FEBS Lett 1985; 188:394–400.

    Article  PubMed  CAS  Google Scholar 

  54. Wondisford FE, Radovick S, Moates JM, et al. Isolation and characterization of the human thyrotropin-beta subunit gene. J Biol Chem 1988; 263:12,538–12,542.

    PubMed  CAS  Google Scholar 

  55. Watanabe S, Hayashizaki Y, Endo Y, et al. Production of human thyroid stimulating hormone in Chinese hamster ovary cells. Biochem Biophys Res Commun 1987; 149:1149–1155.

    Article  PubMed  CAS  Google Scholar 

  56. Hussain A, Zimmerman CA, Boose JA, et al. Large scale synthesis of recombinant human thyrotropin using methotrexate amplification: chromatographic, immunological, and biological characterization. J Clin Endocrinol Metab 1996; 81:1184–1188.

    Article  PubMed  CAS  Google Scholar 

  57. Cole ES, Lee K, Lauziere K, et al. Recombinant human thyroidstimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology 1993; 11:1014–1024.

    Article  PubMed  CAS  Google Scholar 

  58. Wondisford FE, Usala SJ, DeCherney GS, et al. Cloning of the human thyrotropin β-subunit gene and transient expression of biologically active human thyrotropin after gene transfection. Mol Endocrinol 1988; 2:32–39.

    PubMed  CAS  Google Scholar 

  59. Huber GK, Fong P, Concepciín ES, Davies TF. Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab 1 1991; 72:1328–1331.

    CAS  Google Scholar 

  60. Leitolf H, Szkudlinski MW, Thotakura NR, et al. Effects of continuous and pulsatile administration of pituitary rat thyrotropin and recombinant human thyrotropin in a chronically cannulated rat. Horm Metab Res 1995; 27:173–178.

    PubMed  CAS  Google Scholar 

  61. East-Palmer J, Szkudlinski MW, Lee J, et al. A novel nonradio-active in vivo bioassay of thyrotropin (TSH). Thyroid 1995; 5:55–59.

    PubMed  CAS  Google Scholar 

  62. Colzani RM, Alex S, Fang S-L, et al. The effect of recombinant human thyrotropin (rhTSH) on thyroid function in mice and rats. Thyroid 1998; 8:797–801.

    PubMed  CAS  Google Scholar 

  63. Braverman LE, Pratt BM, Ebner S, Longcope C. Recombinant human thyrotropin stimulated thyroid function and radioactive iodine uptake in the rhesus monkey. J Clin Endocrinol Metab 1992; 74:1135–1139.

    Article  PubMed  CAS  Google Scholar 

  64. Ramirez L, Braverman LE, White B, Emerson CE. Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. J Clin Endocrinol Metab 1997; 82:2836–2839.

    Article  PubMed  CAS  Google Scholar 

  65. Ringel MD, Ladenson PW. Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J Clin Endocrinol Metab 1996; 81:1724–1725.

    Article  PubMed  CAS  Google Scholar 

  66. Rudavsky AZ, Freeman LM. Treatment of scan-negative, thyroglobulinpositive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab 1997; 82:9–10.

    Article  Google Scholar 

  67. Meier CA, Braverman LE, Ebner SA, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994; 78:188–196.

    Article  PubMed  CAS  Google Scholar 

  68. Albrecht RR, Ewing SJ. Standardizing administration of the Profile of Moods States (POMS): development of alternative word lists. J Personal Assess 1989; 53:31–39.

    Article  CAS  Google Scholar 

  69. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84:3877–3885.

    Article  PubMed  CAS  Google Scholar 

  70. Cailleux AF, Baudin E, Travagli JP, et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000; 85:175–178.

    Article  PubMed  CAS  Google Scholar 

  71. Baudin E, Do Cao C, Cailleux AF, et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of followup after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003; 88:1107–1111.

    Article  PubMed  CAS  Google Scholar 

  72. Robbins RJ, Chon JT, Fleisher M, et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002; 87:3242–3247.

    Article  PubMed  CAS  Google Scholar 

  73. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87:1490–1498.

    Article  PubMed  CAS  Google Scholar 

  74. Wartofsky L, et al. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 2002; 12:583–590.

    Article  PubMed  CAS  Google Scholar 

  75. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:1433–1441.

    Article  PubMed  CAS  Google Scholar 

  76. Ladenson PW. Recombinant human thyrotropin symposium: Strategies for thyrotropin use to monitor patients with treated thyroid carcinoma. Thyroid 1999; 9:429–433.

    PubMed  CAS  Google Scholar 

  77. Mazzaferri EL. Recombinant human thyrotropin symposium: An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999; 9:421–427.

    PubMed  CAS  Google Scholar 

  78. Ribela MT, Bianco AC, Bartolini P. The use of recombinant human thyrotropin produced by Chinese hamster ovary cells for the preparation of immunoassay reagents. J Clin Endocrinol Metab 1996; 81:249–256.

    Article  PubMed  CAS  Google Scholar 

  79. Morgenthaler NG, Pampel I, Aust G, et al. Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor. Horm Metab Res 1998; 30:162–168.

    PubMed  CAS  Google Scholar 

  80. Szkudlinski MW, Teh NG, Grossman M, et al. Engineering human glycoprotein hormone superactive analogues. Nature Biotechnol 1996; 14:1257–1263.

    Article  CAS  Google Scholar 

  81. Grossmann M, Leitolf H, Weintraub BD, et al. A novel strategy for rational design of protein hormone superagonists. Nature Biotechnol 1998; 16:871–875.

    Article  CAS  Google Scholar 

  82. Weintraub BD, Szkudlinski MW. Recombinant human thyrotropin symposium: development and in vitro characterization of human recombinant thyrotropin. Thyroid 1999; 9:447–450.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisions of Endocrinology and Oncology and Human Cancer Genetics, Ohio State University, Columbus, OH

    Matthew D. Ringel MD (Associate Professor of Medicine)

  2. Division of Endocrinology, Department of Medicine, Ohio State University, Columbus, OH

    Stephen J. Burgun MD (Assistant Professor of Medicine)

Authors
  1. Matthew D. Ringel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen J. Burgun MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Washington Hospital Center, Washington, DC

    Leonard Wartofsky MD, MPH, MACP  & Douglas Van Nostrand MD, FACP, FACNP  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Ringel, M.D., Burgun, S.J. (2006). Recombinant Human Thyrotropin. In: Wartofsky, L., Van Nostrand, D. (eds) Thyroid Cancer. Humana Press. https://doi.org/10.1007/978-1-59259-995-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-995-0_11

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-462-3

  • Online ISBN: 978-1-59259-995-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation